Bekanamycin

Summary

Bekanamycin (CHEMBL176) is a phase-3 clinical-stage small molecule (ATC J01GB13); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01GB13
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 483.5 Da · C18H37N5O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL176
Name	Bekanamycin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	439318
ChEBI	CHEBI:28098
ATC	J01GB13
Molecular formula	C18H37N5O10
Molecular weight	483.5
InChIKey	SKKLOUVUUNMCJE-FQSMHNGLSA-N

SMILES: C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N

IUPAC name: (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol

Also known as: Bekanamicina, Bekanamycin, Bekanamycine, Kanamycin b, Nebramycin v, NK 1006, NK-1006, Kanamycin B, kanamycin B, Aminoglycoside derivative, Kanamysin B, SID144206745

Parent form; salt/anhydrous children: CHEMBL1237048

Patent coverage: 952 distinct patent families (3,090 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-ketoacyl-[acyl-carrier-protein] synthase III.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0A6R0	5.25	IC50	5600	nM	CHEMBL_ACT_17962470

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00508690	PHASE3	COMPLETED	Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics
NCT02409290	PHASE3	COMPLETED	The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
NCT02454205	PHASE2/PHASE3	COMPLETED	An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
NCT00816426	PHASE1	COMPLETED	Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).